The Egyptian Heart Journal · Nov 14, 2026
Clinical outcomes of GLP-1 receptor agonists VS placebo among patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
By Davis E, Alexander L, Tobian N et al.
Background: Heart failure with preserved ejection fraction (HFpEF) is a complex form of heart failure which is marked by impaired diastolic function. It has complex pathophysiology involving systemic inflammation, myocardial fibrosis and arterial stiffness. The existence of other comorbidities namely obesity and diabetes further worsens these processes. Currently there is limited treatment option for HFpEF. Methods: Systematic search from 5 databases was conducted to identify studies that evaluated the impacts of glucagon-like peptide-1 receptor agonist (GLP-1 RA) on the clinical outcomes of HFpEF. Quantitative analysis was performed using random effect model were performed on clinical outcomes. Results are presented as odds ratio (OR) along with its 95% confidence interval. Results: 3 Studies involving 1463 patients were included. GLP-1 RA reduced NT-pro Brain Natriuretic Peptide (NT-pro BNP) levels and enhanced 6-minute walking test, Kansas City Cardiomyopathy Questionnaire clinical summary score. Significant reduction in adjudicated heart failure event was observed (OR 0.32, 95% CI: 0.15–0.67, p < 0.05, I ² = 5%). No significant difference in all-cause mortality (OR 0.63, 95% CI: 0.27–1.48, p = 0.29, I2 = 0%) and cardiovascular mortality (OR 0.27, 95% CI: 0.04–1.66, p = 0.16, I2 = 0%) were observed. Conclusion: GLP-1 RA was effective in improving quality of life parameters and lowered the risk of cardiovascular events of HFpEF patients; however it did not significantly reduce mortality in those who suffered from HFpEF.
doi.org/10.1186/s43044-026-00793-wOpen accessPubMed 43033336Interventions